Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 8, keine Gesamtzahl für „there“
Suchtreffer
Begriffe & Kennungen
Aybintio · 4.8 · Posterior reversible encephalopathy syndrome (see section 4.4) There have been rare reports of bevacizumab-tre
Eintrag öffnenAybintio · 4.8 · There have also been less common reactions of minor mucocutaneous haemorrhage in other locations, such as ging
Eintrag öffnenAyvakyt · 4.5 · Avapritinib is an inhibitor of P-gp, BCRP, MATE1, MATE2-K, and BSEP in vitro. Therefore, avapritinib has the p
Eintrag öffnenAzacitidine Accord · 4.5 · Azacitidine is not a substrate of P-gp, therefore it is not expected to interact with P-gp inducers or inhibit
Eintrag öffnenAzacitidine Accord · 4.8 · Elderly population There is limited safety information available with azacitidine in patients ≥85 years (with
Eintrag öffnenAzacitidine Mylan · 4.8 · Elderly population There is limited safety information available with azacitidine in patients ≥ 85 years (with
Eintrag öffnenAzacitidine betapharm · 4.8 · Elderly population There is limited safety information available with azacitidine in patients ≥ 85 years (with
Eintrag öffnenAzarga · 4.5 · There is a potential for additive effects resulting in hypotension and/or marked bradycardia when an ophthalmi
Eintrag öffnenAzarga · 4.5 · There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in
Eintrag öffnenAzilect · 4.5 · In Parkinson’s disease patients receiving rasagiline as adjunct therapy to chronic levodopa treatment, there w
Eintrag öffnenAzilect · 4.5 · There have been reports of medicinal product interactions with the concomitant use of dextromethorphan and non
Eintrag öffnenAzilect · 4.5 · With MAO inhibitors there have been reports of medicinal product interactions with the concomitant use of symp
Eintrag öffnenBaiama · 4.5 · 6 Adjunctive use of verteporfin photodynamic therapy (PDT) and aflibercept has not been studied, therefore, a
Eintrag öffnenBaiama · 4.5 · Adjunctive use of verteporfin photodynamic therapy (PDT) and aflibercept has not been studied, therefore, a sa
Eintrag öffnenBaiama · 4.8 · As with all therapeutic proteins, there is a potential for immunogenicity with Baiama.
Eintrag öffnenBaiama · 4.8 · As with all therapeutic proteins, there is a potential for immunogenicity with Baiama.
Eintrag öffnenBaiama · 4.8 · In the wet AMD phase III studies, there was an increased incidence of conjunctival haemorrhage in patients rec
Eintrag öffnenBaiama · 4.8 · In the wet AMD phase III studies, there was an increased incidence of conjunctival haemorrhage in patients rec
Eintrag öffnenBalversa · 4.8 · 12 (9.2%). Of patients with events, 4.8% had dose reductions and 6.7% had dose interruptions. There were 1.3%
Eintrag öffnenBaraclude · 4.8 · Gender/age: there was no apparent difference in the safety profile of entecavir with respect to gender ( 25%
Eintrag öffnen